What is Infinity Bio?
Founded in 2023, Infinity Bio, Inc. is a prominent biotechnology firm dedicated to pioneering advanced antibody profiling. Leveraging its proprietary MIPSA technology, the company offers specialized science-as-a-service solutions aimed at enhancing the understanding of immunity. Infinity Bio serves a diverse clientele, including pharmaceutical companies, academic institutions, and the broader biomedical research community, positioning itself as a key innovator in its field.
How much funding has Infinity Bio raised?
Infinity Bio has raised a total of $5M across 1 funding round:
Private Equity
$5M
Private Equity (2025): $5M, investors not publicly disclosed
What's next for Infinity Bio?
The recent major strategic investment signals a pivotal growth phase for Infinity Bio. This substantial backing, part of its {{totalFundingContext}}, is expected to accelerate the company's research and development initiatives, expand its service offerings, and fortify its market presence. The company is poised to further its mission of advancing biomedical research through cutting-edge antibody profiling technologies.
See full Infinity Bio company page
